Daily IPO Digest
Daily Digest — September 29, 2026
Published
Not financial or investment advice, and not a solicitation to buy or sell any security or to use our service. This is AI-assisted analysis of public SEC filings, provided for informational purposes only.
Figures are drawn from those filings and checked against them; any interpretation, conclusion or forecast is our analytical opinion rather than a statement of fact. We do not intend to defame any person or entity.
It is generated by an automated pipeline with no human review and will likely contain factual errors, interpretive errors, and errors of omission that misrepresent the business or the offering — none of them intentional. Do not rely on it as the sole basis for any investment decision. Always do your own research.
Hit the market today
ADARx Pharmaceuticals (ADRX)
ADRX · Biopharma / siRNA · $446 million raised · Nasdaq
ADARx Pharmaceuticals priced at $17.00 per share on 26,250,000 shares, raising $446 million in the offering. A concurrent private placement to AbbVie — capped at $100 million — lifts combined net proceeds to $495 million, or up to $558 million if the greenshoe exercises fully. The company carries zero product revenue: it is a pre-commercial RNA therapeutics platform founded in 2019 with 100 employees. The lead clinical asset is onvuzosiran in hereditary angioedema, enrolled in a 90-patient Phase 3 trial — but the market appears to have priced the extrahepatic siRNA delivery platform, not just the HAE lead. AbbVie's collaboration brought a $335 million upfront payment, up to $385 million in option payments, and up to $7.45 billion in contingent milestones — the milestone ceiling signals the breadth of indications AbbVie is underwriting. AbbVie holds a 4.9% post-IPO stake. Pro forma cash reaches $924 million with a disclosed runway into 2030; R&D spend was $48,319,000 in H1 2026 against $2.9 million in collaboration revenue, so the burn is real. The full brief unpacks what the platform science does and doesn't justify.
Just filed
Calm Seas Acquisition Corp (CSEA)
CSEA · SPAC · filed to raise up to $300 million · terms not yet set
Calm Seas is a blank-check vehicle focused on energy and maritime, filing to raise up to $300 million at $10.00 per unit, with a greenshoe that could lift the trust to $345 million. The differentiating feature here is the sponsor: Pilgrim Global Advisors discloses a five-year gross annualized return of 40.6% against the MSCI World's 12.1% over the same period, and a ten-year batting average of 21 profitable exits out of 23 investments. Those are not the usual credential-padded SPAC disclosures. The structure is standard: founder shares cost $25,000, the deferred underwriting commission is $12 million payable only at deal close, and Cohen & Company Capital Markets receives 3 million private placement warrants as part of the upfront economics. The combination window runs up to 720 days with an extension ceiling of 36 months. The sponsor track record earns more than routine attention at unit pricing; the embedded conflicts — deferred fee, underwriter warrants, sponsor carry — are real and worth reading against it.
MED-X, INC. (MXRX)
MXRX · Natural pest control / CPG · terms not yet set
Med-X makes Nature-Cide, a plant-oil-based pest-control line, alongside a thermal therapy device (Thermal Aid) and a small personal care brand. Founded in 2014, the company has raised $38,081,204 in net proceeds since inception to build a business doing $1.99 million in annual revenue. Nature-Cide is the growth story — revenue rose 34% year-over-year in H1 2026 — but Thermal Aid and Malibu Brands both contracted in the same period. Total operating expenses in H1 2026 were $7.9 million against gross profit of $296,051, a gap driven largely by non-cash stock compensation — option grants alone ran $5.1 million in the first half. The filing carries a going-concern note with a pro forma runway of 15 months, contingent on closing a $30 million committed equity facility from Streeterville Capital concurrently with the Nasdaq listing. The CEO holds 51% voting control via Series A preferred shares. Supplier concentration is stark: the top two vendors represent 80% of purchases, and the top three customers accounted for 68% of receivables in the most recent quarter. The Streeterville close is the binary that determines whether this listing has a follow-on chapter.
Orange Street Acquisition Corp
No ticker yet · SPAC · filed to raise up to $65 million · Nasdaq · terms not yet set
Orange Street Acquisition Corp is a micro-SPAC filing to raise up to $65 million at $10.00 per unit, with the trust funded at $10.05 per unit. The sponsor paid $25,000 for founder shares representing 28% of post-IPO equity — the economics are structurally skewed toward consummating any deal rather than the right deal, which is unremarkable for SPACs but is more exposed at this trust size. The combination deadline is 12 months, one of the tighter clocks in the current market, and the deferred underwriting commission is 5% of the offering, payable only on deal close. No sector focus or pipeline is disclosed. At this trust size, the viable target universe is narrow; the 12-month window gives limited runway to be selective.
Sources
Regulatory filings
- SEC filings
Some figures are computed from the source material above.